接受抗TNF治疗的风湿性疾病患者接种BA.4-5适应性加强疫苗后的抗体反应有限：病例系列结果 - Suppr | 超能文献

相似文献

1

Limited antibody response after BA.4-5 adapted booster vaccination in rheumatic patients receiving anti-TNF therapy: Results of a case series.接受抗TNF治疗的风湿性疾病患者接种BA.4-5适应性加强疫苗后的抗体反应有限：病例系列结果

J Med Virol. 2023 Dec;95(12):e29263. doi: 10.1002/jmv.29263.

2

Reduced neutralizing antibody response in naïve Covishield vaccinees against Omicron emphasizes booster vaccination.初次接种Covishield疫苗者对奥密克戎的中和抗体反应降低，这凸显了加强接种的重要性。

J Infect. 2022 Jul;85(1):90-122. doi: 10.1016/j.jinf.2022.04.031. Epub 2022 Apr 21.

3

Antibody response to SARS-CoV-2 WT and Omicron BA.4/5 of inactivated COVID-19 vaccine in patients with lung cancer after second and booster immunization.接种 2 剂和加强针后，肺癌患者对灭活 COVID-19 疫苗的 SARS-CoV-2 WT 和奥密克戎 BA.4/5 的抗体反应。

J Hematol Oncol. 2023 May 3;16(1):47. doi: 10.1186/s13045-023-01443-3.

4

Anti-tumor necrosis factor therapy is associated with attenuated humoral response to SARS-COV-2 vaccines in patients with inflammatory bowel disease.抗肿瘤坏死因子治疗与炎症性肠病患者对 SARS-CoV-2 疫苗的体液免疫应答减弱相关。

Vaccine. 2023 Jun 13;41(26):3862-3871. doi: 10.1016/j.vaccine.2023.05.012. Epub 2023 May 8.

5

Long-term variations and potency of neutralizing antibodies against Omicron subvariants after CoronaVac-inactivated booster: A 7-month follow-up study.科兴新冠灭活疫苗加强免疫后对奥密克戎变异株的中和抗体持久性和效力：7 个月随访研究。

J Med Virol. 2023 Jan;95(1):e28279. doi: 10.1002/jmv.28279. Epub 2022 Nov 11.

6

The long term vaccine-induced anti-SARS-CoV-2 immune response is impaired in quantity and quality under TNFα blockade.TNFα 阻断会损害长期疫苗诱导的抗 SARS-CoV-2 免疫应答的数量和质量。

J Med Virol. 2022 Dec;94(12):5780-5789. doi: 10.1002/jmv.28063. Epub 2022 Aug 19.

7

Serum neutralization of SARS coronavirus 2 Omicron sublineages BA.1 and BA.2 and cellular immune responses 3 months after booster vaccination.接种加强针 3 个月后，血清对 SARS-CoV-2 奥密克戎亚谱系 BA.1 和 BA.2 的中和作用及细胞免疫应答

Clin Microbiol Infect. 2023 Feb;29(2):258.e1-258.e4. doi: 10.1016/j.cmi.2022.10.014. Epub 2022 Oct 17.

8

Second five-year follow-up after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates at least 10 years antibody persistence.加强免疫 tick-borne encephalitis 疫苗接种后第 5 年随访，至少 10 年抗体持续存在。不同初级免疫接种方案。

Vaccine. 2019 Jul 26;37(32):4623-4629. doi: 10.1016/j.vaccine.2017.12.081. Epub 2018 Feb 1.

9

Comparison of Homologous and Heterologous Booster SARS-CoV-2 Vaccination in Autoimmune Rheumatic and Musculoskeletal Patients.自身免疫性风湿和肌肉骨骼疾病患者中同源和异源加强 SARS-CoV-2 疫苗接种的比较。

Int J Mol Sci. 2022 Sep 27;23(19):11411. doi: 10.3390/ijms231911411.

10

Ancestral SARS-CoV-2 and Omicron BA.5-specific neutralizing antibody and T-cell responses after Omicron bivalent booster vaccination in previously infected and infection-naive individuals.先前感染和未感染个体接种奥密克戎二价加强针后针对原始 SARS-CoV-2 和奥密克戎 BA.5 的中和抗体和 T 细胞应答。

J Med Virol. 2023 Aug;95(8):e28989. doi: 10.1002/jmv.28989.

引用本文的文献

1

Anti-TNF therapy impairs both short- and long-term IgG responses after repeated vaccination.抗TNF治疗会损害重复接种疫苗后的短期和长期IgG反应。

Allergy. 2025 Feb;80(2):423-439. doi: 10.1111/all.16241. Epub 2024 Jul 25.

2

Non-cross-reactive epitopes dominate the humoral immune response to COVID-19 vaccination - kinetics of plasma antibodies, plasmablasts and memory B cells.非交叉反应表位主导 COVID-19 疫苗接种的体液免疫反应 - 血浆抗体、浆母细胞和记忆 B 细胞的动力学。

Front Immunol. 2024 May 14;15:1382911. doi: 10.3389/fimmu.2024.1382911. eCollection 2024.

3

Additional Reassuring Data for SARS-CoV-2 Vaccination in Immune-Mediated Inflammatory Diseases, but With a Catch.